SRI 31215 TFA |
| Katalog-Nr.GC34811 |
SRI 31215 (TFA) ist ein Triplex-Inhibitor von Matriptase/Hepsin/Hepatozyten-Wachstumsfaktor-Aktivator (HGFA) und imitiert die AktivitÄt von HAI-1/2 (endogene Inhibitoren der HGF-Aktivierung). SRI 31215 hat eine starke inhibitorische AktivitÄt gegen Matriptase, Hepsin und HGFA mit IC50-Werten von 0,69 μM, 0,65 μM bzw. 0,30 μM. SRI 31215 kann fÜr die Krebsforschung verwendet werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1832686-44-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SRI 31215 (TFA), a triplex inhibitor of matriptase, hepsin and hepatocyte growth factor activator (HGFA) with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2[1]. IC50: 0.69 μM (matriptase), 0.65 μM (hepsin), 0.3 μM (HGFA)[1]
[1]. Owusu BY, et al. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506.
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *